ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2776

Plasmacytoid Dendritic Cells in Systemic Fibrosis: Pathogenic Role in Bleomycin-Induced Fibrosis Model and Correlation with Disease in Patients with Systemic Sclerosis

Suzanne Kafaja1, Isela Valera2, Anagha Divekar3, Rajan Saggar4, Dinesh Khanna5, Daniel E. Furst6 and Ram R. Singh7, 1Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, 2Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, 3Biolegend, Sa Diego, CA, 4Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 5University of Michigan, Ann Arbor, MI, 6David Geffen School of Medicine at UCLA, Los Angeles, CA, 7Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Dendritic cells, fibrosis, Lung Disease, skin fibrosis and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Innate Immunity and Rheumatic Disease

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

Fibrosis is the end-result of most inflammatory conditions, but its pathogenesis remains unclear. Studies in patients and animal models suggest a role for T-cells and innate immune cells including dendritic cells (DC) in the development of fibrosis. DCs play a role in T-cell priming and differentiation also infiltrate the lung in response to bleomycin injection in animals. DCs also accumulate in lungs of patients with idiopathic pulmonary fibrosis and in skin of patients with systemic sclerosis (SSc) . However, the exact role of DCs in the pathogenesis of fibrotic diseases including SSc is unclear. We investigated the role of plasmacytoid dendritic cells (pDC) in the pathogenesis of systemic fibrosis using the bleomycin model and clinical samples from patients with systemic sclerosis (SSc).

Methods:

Female C57BL/6 mice were depleted of pDCs using anti-pDCA1 and were compared to mice depleted with isotype control IgG2b. clinical observation and analyses were carried of draining LN, spleen, lungs and skin including flow cytometry, pathology, collagen production and RT PCR array. In our work, we evaluated human data (HRCT and BAL) from SSc Imatinib trial. We also examined pDCs in Peripheral blood, skin and lung in controls as well as SSc patients.

Results:

pDCs were more profoundly increased than other immune cells in the lung and lung-draining lymph nodes, but not in the spleen, of bleomycin-injected mice compared to control animals. Depletion of pDCs improved the clinical score, lung histopathology score, skin thickness, and collagen content compared to control antibody-treated animals. B-cells, T-cells and natural killer T-cells were reduced in the lungs, but unaffected/increased in the spleen, of pDC-depleted mice as compared to controls. pDC-depleted mice also had a reduced expression of genes involved in chemotaxis, dendritic cell differentiation, inflammation, and fibrosis in the lungs as compared to controls. In humans, while pDCs were reduced in the peripheral blood of patients with SSc compared to healthy donors, their numbers were increased in the lung and skin of patients with SSc. The frequencies of pDCs in the bronchoalveolar lavage (BAL) correlated with SSc-lung disease scores and with IL-4+ and CD4+ T-cells in BAL.

Conclusion:

Taken together, our observations identify the increased trafficking to pDCs to the affected organs as a potential therapeutic target in fibrotic diseases.


Disclosure: S. Kafaja, None; I. Valera, None; A. Divekar, None; R. Saggar, None; D. Khanna, Actelion, Bayer, BoehringerIngelheim, Chemomab, Corbus, Covis, Cytori,Eicos, EMD Serono, Genentech/Roche, Gilead, GSK, Sanofi-Aventis,UCB Pharma, 5,NIH/NIAMS, NIH/NIAID,Bayer, BMS, Genentech/Roche, Pfizer, 2,Eicos, 4; D. E. Furst, Grant/Research Support: Amgen,BMS Novartis, Pfizer, Roche/Genentech,Corbus. Consultant:AbbVie, Amgen, BMS, Corbus, Cytori, , Novartis, Pfizer, Roche/Genentech,. Speakers Bureau(CME or non-promotional only): BMS, Abbvie NO stocks, royalties, direct fina, 2,see above, 5,see above, 8; R. R. Singh, None.

To cite this abstract in AMA style:

Kafaja S, Valera I, Divekar A, Saggar R, Khanna D, Furst DE, Singh RR. Plasmacytoid Dendritic Cells in Systemic Fibrosis: Pathogenic Role in Bleomycin-Induced Fibrosis Model and Correlation with Disease in Patients with Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/plasmacytoid-dendritic-cells-in-systemic-fibrosis-pathogenic-role-in-bleomycin-induced-fibrosis-model-and-correlation-with-disease-in-patients-with-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/plasmacytoid-dendritic-cells-in-systemic-fibrosis-pathogenic-role-in-bleomycin-induced-fibrosis-model-and-correlation-with-disease-in-patients-with-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology